Personalised Breast Cancer Program - Main study
Research type
Research Study
Full title
Personalised Breast Cancer Program - Main Study
IRAS ID
246732
Contact name
Stephen Kelleher
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Duration of Study in the UK
15 years, 11 months, 30 days
Research summary
PBCP will sequence the healthy genome (DNA and RNA) of 2000 patients diagnosed with breast cancer as well as the genome of their tumour, in order to learn how to adapt cancer treatment by looking at the genome of the tumour.
The aims of this program are to facilitate new discoveries that will help us understand why some people are cured of their cancer, and others are not. It will also contribute to improving our understanding of why some people experience more side-effects than others. It will support clinicians and researchers to develop new therapies and diagnostic tests, and it will also help the NHS to develop genomic medicine to benefit cancer patients.
The PBCP will assess the role of Whole Genome Sequencing (WGS) and RNA sequencing (RNAseq) in the clinical management of breast cancer patients. To do this, the PBCP will examine the genomes of patients with breast cancer and return the results of the sequencing, which are relevant to breast cancer or its treatment, to a patient within 12 weeks. As part of this program, we will collect blood and tissue samples from patients at various time points so that we can produce genetic “fingerprints” from the breast cancer, which we can then analyse and compare using a variety of laboratory techniques.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
18/EE/0251
Date of REC Opinion
2 Oct 2018
REC opinion
Favourable Opinion